The role of bisphosphonates in multiple myeloma

Annals of Internal Medicine

Volumn 132, Issue 9, 2000, Pages 734-736

  Kyle, Robert A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; MELPHALAN; MEVINOLIN; PAMIDRONIC ACID; PREDNISONE; SIMVASTATIN; ZOLEDRONIC ACID;

BONE DESTRUCTION; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; MULTIPLE MYELOMA; OSTEOPENIA; PRIORITY JOURNAL;

EID: 0034595409     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-9-200005020-00009     Document Type: Editorial

References (19)

1. Coukell AJ, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging. 1998;12:149-68.
2. Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med. 1999;50:237-48.
3. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-21.
4. Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol. 1991;9:1397-402.
5. Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, et al. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol. 1990;8:23-30.
6. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992;340:1049-52.
7. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998;100:317-25.
8. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol. 1997;37:285-90.
9. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-93.
10. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patents reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593-602.
11. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish Co-operative Study Group. Br J Haematol. 1998;101:280-6.
12. Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, et al. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol. 1998;61:128-34.
13. Fontana A, Herrmann Z, Menssen HD, Sakalova A, Boewer C, Facon T, et al. Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma [Abstract]. Blood. 1998;92 Suppl 1:106a.
14. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997;98:665-72.
15. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998;58: 5294-7.
16. Sjak-Shie NN, Tsingotjidou AS, Zhang K, Vescio RA, Said JW, Lieberman J, et al. Development of a SCID-hu animal model that more closely resembles human multiple myeloma (Abstract]. Blood. 1999;94 Suppl 1:547a.
17. Yaccoby S, Barlogie B, Epstein J. Pamidronate inhibits growth of myeloma in vivo in the SCID-hu system [Abstract]. Blood 1998;92 Suppl 1:106a.
18. Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, et al. Anti-myeloma activity of pamidronate in vivo. Br J Haematol. 1998;103: 530-2.
19. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-9.